Inventiva
IVA
Inventiva (IVA) news
Recent news
Inventiva SA: Truist Securities raises target price to $18 from $13
Truist Securities has raised its price target for Inventiva SA (EPA:IVX) to $18 from $13, maintaining its "Buy" rating on the stock ahead of anticipated phase 3 clinical trial data . The updated target reflects the firm’s confidence in the company’s near-term catalysts and potential for positive…
AInvest Wire · Oct 2, 2026Shares in Inventiva down 10.5%
AInvest Wire · Oct 1, 2026Inventiva SA - Cash runway guidance remains unchanged from July 30, 2026
AInvest Wire · Sep 28, 2026Inventiva SA - Topline results of phase 3 Nativ3 clinical trial are expected in Q4 of 2026
AInvest Wire · Sep 28, 2026Inventiva - Expects to finance operations as planned until end of Q2 2027
AInvest Wire · Sep 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.